These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 24220253)

  • 21. Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting.
    Grey AD; Chana MS; Popert R; Wolfe K; Liyanage SH; Acher PL
    BJU Int; 2015 May; 115(5):728-35. PubMed ID: 25041307
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer.
    Somford DM; Hoeks CM; Hulsbergen-van de Kaa CA; Hambrock T; Fütterer JJ; Witjes JA; Bangma CH; Vergunst H; Smits GA; Oddens JR; van Oort IM; Barentsz JO;
    Invest Radiol; 2013 Mar; 48(3):152-7. PubMed ID: 23328910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
    BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis.
    Hamoen EHJ; de Rooij M; Witjes JA; Barentsz JO; Rovers MM
    Eur Urol; 2015 Jun; 67(6):1112-1121. PubMed ID: 25466942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiparametric magnetic resonance imaging in the detection of prostate cancer.
    Durmus T; Baur A; Hamm B
    Rofo; 2014 Mar; 186(3):238-46. PubMed ID: 24452493
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer.
    Felker ER; Lee-Felker SA; Feller J; Margolis DJ; Lu DS; Princenthal R; May S; Cohen M; Huang J; Yoshida J; Greenwood B; Kim HJ; Raman SS
    Abdom Radiol (NY); 2016 May; 41(5):954-62. PubMed ID: 27118268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy.
    Bryk DJ; Llukani E; Huang WC; Lepor H
    J Urol; 2015 Nov; 194(5):1234-40. PubMed ID: 26003206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic resonance imaging-guided prostate biopsy: institutional analysis and systematic review.
    Polanec SH; Helbich TH; Margreiter M; Klingler HC; Kubin K; Susani M; Pinker-Domenig K; Brader P
    Rofo; 2014 May; 186(5):501-7. PubMed ID: 24497092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.
    Osses DF; van Asten JJ; Kieft GJ; Tijsterman JD
    World J Urol; 2017 Feb; 35(2):207-212. PubMed ID: 27287889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB.
    Venderink W; Jenniskens SF; Michiel Sedelaar JP; Tamada T; Fütterer JJ
    Korean J Radiol; 2018; 19(4):733-741. PubMed ID: 29962879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
    Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
    Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
    Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
    Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
    Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
    World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
    Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
    J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy.
    Pepe P; Garufi A; Priolo GD; Galia A; Fraggetta F; Pennisi M
    J Urol; 2018 Oct; 200(4):774-778. PubMed ID: 29679618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility.
    van der Leest M; Israël B; Cornel EB; Zámecnik P; Schoots IG; van der Lelij H; Padhani AR; Rovers M; van Oort I; Sedelaar M; Hulsbergen-van de Kaa C; Hannink G; Veltman J; Barentsz J
    Eur Urol; 2019 Nov; 76(5):574-581. PubMed ID: 31167748
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of Prostate Imaging Reporting and Data System Version 2 for the Detection of Prostate Cancer.
    Hofbauer SL; Maxeiner A; Kittner B; Heckmann R; Reimann M; Wiemer L; Asbach P; Haas M; Penzkofer T; Stephan C; Friedersdorff F; Fuller F; Miller K; Cash H
    J Urol; 2018 Oct; 200(4):767-773. PubMed ID: 29733838
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific Antigen Parameters and Prostate Health Index Enhance Prostate Cancer Prediction With the In-bore 3-T Magnetic Resonance Imaging-guided Transrectal Targeted Prostate Biopsy After Negative 12-Core Biopsy.
    Friedl A; Stangl K; Bauer W; Kivaranovic D; Schneeweiss J; Susani M; Hruby S; Lusuardi L; Lomoschitz F; Eisenhuber-Stadler E; Schima W; Brössner C
    Urology; 2017 Dec; 110():148-153. PubMed ID: 28844600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy.
    Kaufmann S; Russo GI; Bamberg F; Löwe L; Morgia G; Nikolaou K; Stenzl A; Kruck S; Bedke J
    World J Urol; 2018 May; 36(5):761-768. PubMed ID: 29380130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.